澤珂和安可坦在現實狀況的有效性-來自台中童綜合醫院的經驗分享
盧顥文、黃立華、歐宴泉
童綜合醫院外科部泌尿外科
The efficacy of abiraterone and enzalutamide in a real life situation- The experience fromTung’s Taichung MetroHarbor Hospital
Hao-Wen LU, Li-Hua Huang, Yen-Chuan Ou
Divisions of Urology, Department of Surgery, Tungs’Taichung MetroHarbor Hospital, Taichung, Taiwan

Objective: The objective of this study is to share our own experience about the efficacy of Abiraterone(Abi) and enzalutamide(Enza) in real life setting

Materials and Methods: From August 2016 to December 2018, we retrospective review data of 48 patients who received Aibiraterone(1000mg with 5mg twice daily) and 39 patients received Enzalutamide(160mg daily) for the treatment of castration resistant prostate cancer. The sub group is further divided to previously received chemotherapy or chemotherapy naive patients. Our primary end point is to evaluate the prostate specific antigen(PSA) response rate(defined as PSA decline > 50 % from the base line) in Abi and Enza groups. Our secondary end point are the duration of treatment (DoT) of Abi and Enza   

Results: In Abi group, the PSA response rate is 61% in chemotherapy naive patients and 45 % in post chemotherapy group with median DoT of 7.1 and 5.7 months. In Enza group, The PSA response rate is 75% and 60% in chemotherapy naive and post chemotherapy sub groups. The median DoT is 6.6 and 6.3 months, respectively.  

Conclusions: In our single center experience, compared to PREVAIL and AFFIRM study, Enza showed similar PSA response rate with shorter DOT in chemotherapy naive and post chemotherapy subgroups. In Abi group, compared to COUAA-302 and COUAA-302, Abi showed better PSA response rate in chemotherapy naive and post chemotherapy group, however, shorter DoT was noticed due to this studying is continue going. The better PSA response rate and PRA-PFS in Taiwanese patients will be further study歐I